Finasteride, a synthetic 4-azasteroid compound, is a specific competitive inhibitor of type II 5-alpha reductase, an intracellular enzyme that converts testosterone into a more active androgen-dihydrotestosterone (DHT). In BPH, its increase depends on the conversion of testosterone to DHT in the prostate. Finasteride is highly effective in reducing the concentration of DHT in both plasma and prostate tissue. Suppression of DHT formation is accompanied by a decrease in the size of the prostate gland, an increase in the maximum rate of urination and a decrease in the severity of symptoms associated with prostatic hyperplasia.
Finasteride does not have an affinity for androgen receptors.
Indications for use
Treatment of benign prostatic hyperplasia in order to:
- reducing the size of the enlarged prostate gland, improving urine flow and reducing the severity of symptoms associated with benign prostatic hyperplasia;
- Prevention of urological complications (reducing the risk of acute urinary retention) and reducing the need for surgical operations (including transurethral resection of the prostate and prostatectomy). Contraindications
Hypersensitivity to finasteride and other components of the drug; Obstructive uropathy; Lactose intolerance; Lactase deficiency; Glucose-galactose malabsorption syndrome; For use in women; Age to 18 years.